Case Study: Corcept Therapeutics accelerates first-in-human drug development with Quotient Sciences

Corcept Therapeutics accelerates drug development by 12 months with Quotient Sciences

Corcept Therapeutics, a pharmaceutical company based in California, faced a challenge in developing their next-generation selective glucocorticoid receptor antagonist, CORT125134. They needed to accelerate the development process and required a solution that integrated clinical trial manufacturing with clinical testing. They approached Quotient Sciences for its integrated services to address this need.

Quotient Sciences implemented its Translational Pharmaceutics® platform, which combined drug product formulation, manufacturing, and clinical testing within a single, integrated program. This accelerated approach, performed at Quotient Sciences' facilities, helped Corcept Therapeutics reduce its drug development timelines by as much as 12 months, delivering significant time and cost savings.

Corcept Therapeutics